Methotrexate Arrow (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is needed to produce tetrahydrofolate, a co‑factor for purine and pyrimidine synthesis. By limiting these building blocks, the drug hampers DNA replication and cell division, affecting rapidly dividing immune cells and tumor cells, thereby providing immunosuppressive and antineoplastic effects.

The dose of Methotrexate Arrow is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Only a qualified healthcare professional should determine the appropriate regimen and schedule.

Methotrexate Arrow is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as it may be excreted in breast milk and affect the infant. Effective contraception is required for women of child‑bearing potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with biologic agents, methotrexate is a small‑molecule antimetabolite that is taken orally and is generally less expensive. While biologics target specific cytokines, methotrexate has a broader mechanism affecting DNA synthesis. Efficacy varies by disease; methotrexate is often first‑line for rheumatoid arthritis and psoriasis, whereas biologics may be added for refractory cases.

Methotrexate Arrow should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Methotrexate Arrow is administered orally, typically as a tablet swallowed with water. The exact dosing schedule—such as weekly versus daily dosing—depends on the condition being treated and is determined by the prescribing physician.

Serious risks include severe liver toxicity, pulmonary fibrosis, significant bone‑marrow suppression leading to anemia or infection, and renal failure. Patients should be monitored regularly for liver enzymes, blood counts, and kidney function, and any signs of infection or respiratory distress should prompt immediate medical evaluation.

Methotrexate Arrow should not be used by pregnant or breastfeeding women, individuals with severe liver disease, uncontrolled renal impairment, or known hypersensitivity to methotrexate. It is also contraindicated in patients receiving certain interacting medications without appropriate monitoring.